FNY Investment Advisers’s BridgeBio Pharma BBIO Stock Holding History

FNY Investment Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,500	Closed	-$151K	–	1244
2025 Q2	$151K	Sell	3,500 -7,836	-69%	-$285K	0.06%	245
2025 Q1	$391K	Sell	11,336 -2,414	-18%	-$81.4K	0.24%	93
2024 Q4	$377K	Buy	13,750 +5,100	+59%	+$132K	0.2%	107
2024 Q3	$220K	Buy	8,650 +2,900	+50%	+$76.1K	0.11%	161
2024 Q2	$145K	Buy	5,750 +2,000	+53%	+$54.7K	0.1%	145
2024 Q1	$115	Buy	+3,750	New	+$128K	0.07%	169
2023 Q3	–	Sell	-1,000	Closed	-$28.4K	–	611
2023 Q2	$17K	Hold	1,000	–	–	0.02%	259
2023 Q1	$16K	Buy	+1,000	New	+$11.7K	0.02%	291
2019 Q3	–	Sell	-256	Closed	-$6K	–	891
2019 Q2	$6K	Buy	+256	New	+$6.98K	﹤0.01%	660

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FNY Investment Advisers's BBIO Position: Q3 2025 in Review

FNY Investment Advisers sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 3,500 shares — an estimated $151K sold.

FNY Investment Advisers first reported a position in BBIO in Q2 2019 and held it in 9 quarters. The position peaked at $391K in Q1 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

FNY Investment Advisers reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
FNY Investment Advisers sold 3,500 BridgeBio Pharma shares in Q3 2025, an estimated $151K.
FNY Investment Advisers first reported a position in BridgeBio Pharma in Q2 2019 and held it in 9 quarters.
FNY Investment Advisers's BridgeBio Pharma position peaked at $391K in Q1 2025.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on FNY Investment Advisers's 13F filing for Q3 2025, filed 15 Dec 2025.